TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17561543

Group type: EXPERIMENTAL
Intervention: Indiplon 15 mg nightly
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 14563205

Group type: EXPERIMENTAL
Intervention: Halometer device used to detect and quantify halos after LASIK surgery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Halometer device used with normal subjects
Number of subjects: 0
Study: 10981559

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 16 mg once daily for 6 weeks
Number of subjects: 0
Study: 9108638

Group type: EXPERIMENTAL
Intervention: Ropivacaine hydrochloride 20 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ropivacaine hydrochloride 40 mg
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ropivacaine hydrochloride 80 mg
Number of subjects: 3
Study: 8251889

Group type: EXPERIMENTAL
Intervention: IFN (human recombinant interferon‐alpha 2a, ROFERON‐A)
Number of subjects: 597

Group type: EXPERIMENTAL
Intervention: ROFERON‐A for 1 year
Number of subjects: 597

Group type: COMPARATOR
Intervention: Hydroxyurea
Number of subjects: 597
Study: 3814215

Group type: EXPERIMENTAL
Intervention: Amcinonide, betamethasone 17-valerate, triamcinolone acetonide (alcoholic solutions)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Clobetasol 17-propionate (ointment)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Kerosene test
Number of subjects: 14
Study: 31682163

Group type: EXPERIMENTAL
Intervention: Positive screening for ankylosing spondylitis (AS)
Number of subjects: 4916

Group type: EXPERIMENTAL
Intervention: Confirmed diagnosis of ankylosing spondylitis (AS)
Number of subjects: 4916

Group type: EXPERIMENTAL
Intervention: Prevalence of ankylosing spondylitis (AS)
Number of subjects: 4916
Study: 28678558

Group type: EXPERIMENTAL
Intervention: Cysteamine cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 27156228

Group type: EXPERIMENTAL
Intervention: Acupuncture alone (A)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Morphine alone (M)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Acupuncture and morphine (AM)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control (not applicable)
Number of subjects: 173
Study: 25336916

Group type: COMPARATOR
Intervention: Fimasartan 120 mg (single oral dose)
Number of subjects: 16
Study: 24040278

Group type: EXPERIMENTAL
Intervention: HRQL assessments using PedsQL 4.0 Generic Core Scales, PedsQL 3.0 Acute Cancer Module, PedsQL Multidimensional Fatigue Scale, Pediatric Inventory for Parents
Number of subjects: 906
Study: 20825523

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg) daily for 3 months
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 18315942

Group type: EXPERIMENTAL
Intervention: Fixed-combination bimatoprost 0.03%/timolol 0.5% administered once daily
Number of subjects: 5

Group type: COMPARATOR
Intervention: Fixed-combination travoprost/timolol
Number of subjects: 5

Group type: COMPARATOR
Intervention: Fixed-combination latanoprost/timolol
Number of subjects: 5
Study: 15764761

Group type: EXPERIMENTAL
Intervention: Tiotropium (18 microg qd) during 8 weeks of pulmonary rehabilitation (PR)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo during 8 weeks of pulmonary rehabilitation (PR)
Number of subjects: 93
Study: 14706505

Group type: EXPERIMENTAL
Intervention: LHRH agonist therapy (immediate adjuvant therapy after prostatectomy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant therapy with radiation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (LHRH agonist + nonsteroidal antiandrogen)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intermittent hormone therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LHRH agonist therapy
Number of subjects: 0
Study: 10998836

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg rocuronium
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg rocuronium
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg rocuronium (females)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium (females)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg rocuronium (females)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg rocuronium (males)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg rocuronium (males)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 0.9 mg/kg rocuronium (males)
Number of subjects: 108
Study: 8844446

Group type: EXPERIMENTAL
Intervention: Felbamate (1,200 mg every 12 hours)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 1346794

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Salbutamol (200 micrograms)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 6835892

Group type: EXPERIMENTAL
Intervention: Meptazinol
Number of subjects: 22
Study: 30359684

Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg twice daily for seven days
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 200
Study: 29017535

Group type: EXPERIMENTAL
Intervention: LeucoPatch® device applied in addition to good standard care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Good standard care (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LeucoPatch® device
Number of subjects: 0
Study: 25840543

Group type: EXPERIMENTAL
Intervention: High-concentration supplemental perioperative oxygen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24121083

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided SIJ injections
Number of subjects: 120

Group type: COMPARATOR
Intervention: Fluoroscopy-guided SIJ injections
Number of subjects: 120
Study: 22682323

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg three times a week
Number of subjects: 92

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study: 19542193

Group type: EXPERIMENTAL
Intervention: Text message communication (n = 193)
Number of subjects: 402

Group type: COMPARATOR
Intervention: Card enquiry (n = 209)
Number of subjects: 402

Group type: EXPERIMENTAL
Intervention: Text message communication
Number of subjects: 402
Study: 18076292

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba (80 mg/12 h)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Acetazolamide (250 mg/12 h)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba
Number of subjects: 36
Study: 15044399

Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 139

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 139
Study: 16108864

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 10614810

Group type: EXPERIMENTAL
Intervention: Contrast-enhanced transthoracic echocardiography
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cine magnetic resonance imaging
Number of subjects: 0
Study: 9005613

Group type: EXPERIMENTAL
Intervention: Antioxidant trimetazidine (Preductal)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Standard therapy (thrombolytic drugs, beta‐blockers, APP inhibitors, nitrates, aspirin)
Number of subjects: 86
Study: 1883434

Group type: EXPERIMENTAL
Intervention: Personal statements from fictitious residency candidates (three men, three women)
Number of subjects: 6064
Study: 6979982

Group type: EXPERIMENTAL
Intervention: Propranolol 10 mg every 6 hours enterally starting the morning after surgery (Group I, 50 patients)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (Group II, 50 patients)
Number of subjects: 100
Study: 30888251

Group type: EXPERIMENTAL
Intervention: Myoelectric computer interface (MyoCI) training (60 vs 90 minutes)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Myoelectric computer interface (MyoCI) training without arm restraint (90 minutes)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Myoelectric computer interface (MyoCI) training (90 minutes)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Myoelectric computer interface (MyoCI) training
Number of subjects: 32
Study: 30120033

Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT) program for sensori‐motor impairment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Conventional program (control)
Number of subjects: 31
Study: 26847983

Group type: EXPERIMENTAL
Intervention: Periodic limb movements (PLMs)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (BP) elevations with PLMs
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure (BP) elevations with PLMs
Number of subjects: 89
Study: 25533442

Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Number of subjects: 287

Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 287
Study: 22311960

Group type: EXPERIMENTAL
Intervention: MiQuit (tailored self-help leaflet and 11-week tailored text messages)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control (nontailored self-help leaflet)
Number of subjects: 207
Study: 18502028

Group type: EXPERIMENTAL
Intervention: Propiverine (10 or 15 mg twice daily)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 17944740

Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.d. + Placebo
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg b.d. + Ranitidine 300 mg at bedtime
Number of subjects: 14
Study: 15854087

Group type: EXPERIMENTAL
Intervention: 20 mg oral prednisolone once daily perioperatively (Group I, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Identical placebo (Group II, n = 20)
Number of subjects: 40
Study: 12408530

Group type: EXPERIMENTAL
Intervention: Induction group (IFN 3 MU daily for 14 days, then 3 MU three times a week)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Standard group (IFN 3 MU three times a week from start)
Number of subjects: 31
Study: 10225553

Group type: EXPERIMENTAL
Intervention: Conventional radiotherapy (treatment duration up to 48 days)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Conventional radiotherapy (treatment duration 49 or more days)
Number of subjects: 366
Study: 7869940

Group type: EXPERIMENTAL
Intervention: dF 30 mg acutely (n = 6)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: dF 15 mg twice daily for 15 days (chronic)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 11
Study: 31394154

Group type: EXPERIMENTAL
Intervention: Rewarming duration (time from 34°C to 36°C)
Number of subjects: 328
Study: 31607604

Group type: EXPERIMENTAL
Intervention: Oral poliovirus vaccine (OPV) co-administered with RV3-BB
Number of subjects: 1649

Group type: EXPERIMENTAL
Intervention: Inactivated polio vaccine (IPV) co-administered with RV3-BB
Number of subjects: 1649

Group type: COMPARATOR
Intervention: Oral poliovirus vaccine (OPV)
Number of subjects: 1649
Study: 27381488

Group type: COMPARATOR
Intervention: Lecture only (30-min lecture)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Lecture and App (30-min lecture + access to Dental Trauma App)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: App only (access to Dental Trauma App)
Number of subjects: 87
Study: 26242222

Group type: EXPERIMENTAL
Intervention: Test capecitabine tablets (T)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Reference capecitabine tablets (R)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: MTHFR C677T genotype
Number of subjects: 46
Study: 24041978

Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (E+P) therapy
Number of subjects: 16608

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16608
Study: 21747300

Group type: EXPERIMENTAL
Intervention: Resistance Training Group (RTG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Endurance Training Group (ETG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 30
Study: 17623819

Group type: EXPERIMENTAL
Intervention: Glargine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Detemir
Number of subjects: 24
Study: 16217004

Group type: EXPERIMENTAL
Intervention: Professional liability insurance market changes
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Elimination of specific services
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Surgical specialists and general surgeons
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Obstetrician/gynecologists and family medicine physicians
Number of subjects: 727

Group type: EXPERIMENTAL
Intervention: Changes in professional liability insurance premiums
Number of subjects: 727
Study: 12110490

Group type: EXPERIMENTAL
Intervention: Annual screening (invited to three further annual screens)
Number of subjects: 99389

Group type: COMPARATOR
Intervention: 3-yearly screening (invited to the standard single screen 3 years later)
Number of subjects: 99389
Study: 10366230

Group type: COMPARATOR
Intervention: Generalized chronic inflammatory demyelinating polyneuropathy (G-CIDP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Multifocal motor neuropathy (MMN)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Upper limb predominant CIDP (UL-CIDP)
Number of subjects: 10
Study: 7717597

Group type: EXPERIMENTAL
Intervention: Immediate treatment with antimicrobial therapy for 7 days
Number of subjects: 191

Group type: COMPARATOR
Intervention: Delayed treatment (control group)
Number of subjects: 191

Group type: COMPARATOR
Intervention: Non-bacteriuric group
Number of subjects: 191
Study: 2392131

Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole (20 and 100 mg per kilogram of body weight per day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: trimethoprim-dapsone (20 mg per kilogram per day and 100 mg per day)
Number of subjects: 60
Study: 7174862

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 46
Study: 31156265

Group type: EXPERIMENTAL
Intervention: Karo Light syrup
Number of subjects: 24

Group type: COMPARATOR
Intervention: Crown Lily White syrup
Number of subjects: 24
Study: 29040837

Group type: EXPERIMENTAL
Intervention: Grape intake (5 g/kg body weight/day for 3 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no grape intake)
Number of subjects: 30
Study: 26611434

Group type: EXPERIMENTAL
Intervention: 100mg enteric-coated aspirin
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 1262
Study: 23440491

Group type: EXPERIMENTAL
Intervention: Presence of antenatal depressive symptoms (K-10 score >6)
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Vomiting
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Anemia
Number of subjects: 365

Group type: EXPERIMENTAL
Intervention: Nutrient intakes, serum vitamin B12, methylmalonic acid, homocysteine, and red cell folate levels
Number of subjects: 365
Study: 23160103

Group type: EXPERIMENTAL
Intervention: Group A received the debriefing information in the body of an email with links to protocol and results pages.
Number of subjects: 11943

Group type: COMPARATOR
Intervention: Group B was presented with links after clicking on an initial link in the body of the email to view the debriefing information on a website.
Number of subjects: 11943
Study: 19390079

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy during coiling
Number of subjects: 1422

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy after coiling
Number of subjects: 1422

Group type: COMPARATOR
Intervention: No antiplatelet therapy during coiling
Number of subjects: 1422

Group type: COMPARATOR
Intervention: No antiplatelet therapy after coiling
Number of subjects: 1422
Study: 17272770

Group type: EXPERIMENTAL
Intervention: Above median hsCRP level (> or =0.21 mg/L)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Silent cerebral infarcts (SCIs)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Above median hsCRP level and SCIs at baseline
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Below median hsCRP level and SCIs
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Above median hsCRP level without SCIs
Number of subjects: 514
Study: 16276447

Group type: EXPERIMENTAL
Intervention: 1 mL 2% lidocaine and 0.5 mL betamethasone (7 mg/mL)
Number of subjects: 17

Group type: COMPARATOR
Intervention: 1 mL 1% lidocaine and 0.5 mL betamethasone (7 mg/mL)
Number of subjects: 17
Study: 12105256

Group type: EXPERIMENTAL
Intervention: Basiliximab (SIM group) with dual maintenance immunosuppression (prednisolone and cyclosporin A)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Antilymphocyte globulin (ALG group) with triple maintenance immunosuppression (prednisolone, cyclosporin A, and azathioprine)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Basiliximab (SIM group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Antilymphocyte globulin (ALG group)
Number of subjects: 42
Study: 10206565

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Overall interference of pain and emotional upset due to pain
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Threat appraisal
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Challenge appraisal
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Health care utilization
Number of subjects: 309
Study: 7792377

Group type: EXPERIMENTAL
Intervention: Social affiliation (accompanied by a close friend) under high social threat
Number of subjects: 96

Group type: COMPARATOR
Intervention: Social affiliation (alone) under high social threat
Number of subjects: 96

Group type: COMPARATOR
Intervention: Social affiliation (accompanied by a close friend) under low social threat
Number of subjects: 96

Group type: COMPARATOR
Intervention: Social affiliation (alone) under low social threat
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Social affiliation (both conditions)
Number of subjects: 96
Study: 2222942

Group type: EXPERIMENTAL
Intervention: Marine oil (n = 8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vegetable oil (n = 8)
Number of subjects: 16
Study: 693755

Group type: EXPERIMENTAL
Intervention: Feedback training procedure
Number of subjects: 24

Group type: COMPARATOR
Intervention: No feedback training procedure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both feedback and no feedback training procedures
Number of subjects: 24
Study: 31436162

Group type: EXPERIMENTAL
Intervention: Web-based independent intervention
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Face-to-face with nurse consultations
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Web-based with virtual nurse consultations
Number of subjects: 225

Group type: COMPARATOR
Intervention: Control group (Web-based independent)
Number of subjects: 225
Study: 28850255

Group type: EXPERIMENTAL
Intervention: Dynamic CT imaging of the scapholunate joint
Number of subjects: 15
Study: 26938637

Group type: EXPERIMENTAL
Intervention: Ginkgo Biloba (120 mg, 240 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ginseng (500 mg, 1000 mg)
Number of subjects: 24
Study: 24005256

Group type: EXPERIMENTAL
Intervention: Structured complex intervention based on the Theory of Planned Behaviour (TPB) including practice-based education, skill development, and practical resources
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group practices
Number of subjects: 160
Study: 23176985

Group type: EXPERIMENTAL
Intervention: G1: hyperbaric bupivacaine (8 mg), sufentanil (2.5 μg), morphine (100 μg)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: G2: hyperbaric bupivacaine (10 mg), sufentanil (2.5 μg), morphine (100 μg)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: G3: hyperbaric bupivacaine (12.5 mg), morphine (100 μg)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: G4: hyperbaric bupivacaine (15 mg), morphine (100 μg)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: G5: hyperbaric bupivacaine (12.5 mg), morphine (100 μg), without perioperative anti‐inflammatory
Number of subjects: 443
Study: 21085907

Group type: EXPERIMENTAL
Intervention: Vitamin E (900 IU/day P.O. for 6 months)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Exercise training (walking exercise 3 sessions per week for 6 months)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Sedentary control (no intervention)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Vitamin E under training (900 IU/day P.O. for 6 months with exercise)
Number of subjects: 57
Study: 17406822

Group type: EXPERIMENTAL
Intervention: Consensus interferon and ribavirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pegylated interferon and ribavirin
Number of subjects: 0
Study: 16051242

Group type: EXPERIMENTAL
Intervention: 600 microg of misoprostol intravaginally
Number of subjects: 94

Group type: COMPARATOR
Intervention: Surgical curettage
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Medical management (misoprostol)
Number of subjects: 94
Study: 12145066

Group type: EXPERIMENTAL
Intervention: Propofol infusion
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Isoflurane inhalation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combination of isoflurane and propofol
Number of subjects: 60
Study: 10995145

Group type: EXPERIMENTAL
Intervention: EMLA (eutectic mixture of local anaesthetic)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amethocaine
Number of subjects: 20
Study: 7480619

Group type: EXPERIMENTAL
Intervention: Educational intervention with retailers (three educational visits over a 1-year period)
Number of subjects: 236

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Educational intervention with retailers
Number of subjects: 236
Study: 2269834

Group type: EXPERIMENTAL
Intervention: Elastic band mobilisation with conventional forearm attachment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elastic band mobilisation with attachments around the dorsum of the hand or under a palmar pulley
Number of subjects: 0
Study: 7308277

Group type: EXPERIMENTAL
Intervention: Atenolol 100 mg once/day
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg twice/day
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Metoprolol 300 mg once/day
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 31999296

Group type: EXPERIMENTAL
Intervention: High-Dose Chemotherapy (HDCT)
Number of subjects: 885

Group type: COMPARATOR
Intervention: Conventional-Dose Chemotherapy (CDCT)
Number of subjects: 885